Charles A Clevenger

US Patent:

7691812, Apr 6, 2010

Filed:

Oct 26, 2005

Appl. No.:

11/258786

Inventors:

Charles V. Clevenger - Elmhurst IL, US

Assignee:

Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

A61K 38/13

US Classification:

514 11

Abstract:

Methods are provided for inhibiting growth of prolactin-responsive cancer cells and treating prolactin-responsive malignancies via administration of an agent such as cyclosporine A which directly inhibits an enzymatic activity of a cyclophilin.

US Patent:

8357660, Jan 22, 2013

Filed:

Feb 24, 2010

Appl. No.:

12/711580

Inventors:

Charles V. Clevenger - Elmhurst IL, US

Assignee:

The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

A61K 38/13

US Classification:

514 195, 514 205

Abstract:

Methods are provided for inhibiting growth of prolactin-responsive cancer cells and treating prolactin-responsive malignancies via administration an agent such as cyclosporine A which directly inhibits an enzymatic activity of a cyclophilin.

US Patent:

20070092920, Apr 26, 2007

Filed:

Oct 24, 2006

Appl. No.:

11/552498

Inventors:

Charles Clevenger - Elmhurst IL, US
William Sweet - Mountain View CA, US

International Classification:

G01N 33/53
C07K 16/26

US Classification:

435007920, 530388250

Abstract:

The present invention relates to antibodies that have specificity towards prolactin binding protein (PRLBP) that is either bound to a binding partner or unbound to a binding partner, as well as antibodies towards PRLBP regardless of the binding state of PRLBP. The present invention also provides methods of using these PRLBP-specific antibodies, such as method of diagnosing and monitoring the progression of diseases such as epithelial carcinomas, osteoporosis, infertility and cachexia.

US Patent:

20100273188, Oct 28, 2010

Filed:

Feb 26, 2010

Appl. No.:

12/714317

Inventors:

Charles CLEVENGER - Elmhurst IL, US
William Sweet - Mountain View CA, US

Assignee:

LIFE TECHNOLOGIES CORPORATION - Carlsbad CA

International Classification:

G01N 33/68
C07K 16/28
C07K 16/00
C07K 16/26

US Classification:

435 78, 5303871, 5303881, 53038822, 53038824, 436501, 435 79

Abstract:

The present invention relates to antibodies that have specificity towards prolactin binding protein (PRLBP) that is either bound to a binding partner or unbound to a binding partner, as well as antibodies towards PRLBP regardless of the binding state of PRLBP. The present invention also provides methods of using these PRLBP-specific antibodies, such as method of diagnosing and monitoring the progression of diseases such as epithelial carcinomas, osteoporosis, infertility and cachexia.